Yeager, M., et al. I(2007) Nature Genetics 39:645-649] and Sladek, R., et al.
\([(2007) \text { Nature } 445: 881-885]\) have used singlenucleotide
polymorphisms (SNPs) in genome-wide association studies (GWAS) to identify
novel risk loci for prostate cancer and Type 2 diabetes, respectively. Each
study suggests that diseaserisk genes can be identified that significantly
contribute to the disease state. Given your understanding of such complex
diseases, what would you determine as reasonable factors to consider when
interpreting the results of GWAS?